March 4, 2025

How many SPCs are required to satisfy the IL PTE eligibility requirement?

PTE grant and duration in Israel are subject to a series of linkages to PTE/SPCs granted in the US and in the five Recognized European Countries (UK, Germany, France, Italy, Spain). The key eligibility prerequisite is the Two-State rule. It provides that if a marketing approval was granted in the US, a prerequisite for IL […]

December 2, 2024

IL PTE Update: Revocation of a single SPC in the European Recognized Countries invalidates the IL PTE

In a recent decision, the ILPTO clarified the scope of the IL PTE ‘linkage principle’ and held that the revocation of an SPC for a reference patent in any of the European Recognized Countries automatically invalidates the corresponding PTE order in Israel, even if SPCs for reference patents in other European Recognized Countries remain in […]

October 31, 2024

The 2024 Legal 500 Israel Patent Litigation Comparative Guide by Liad Whatstein & Co.

Our firm recently published on the Legal 500 platform an updated Israel chapter for 2024 in the Legal 500 Patent Litigation Comparative Guide. The chapter provides up-to-date information on patent litigation in Israel and covers recent developments. The guide can be consulted on Legal 500’s website, or directly on our website.

July 11, 2024

ILPTO Update: Broad functional antibody claims are not permissible

In a precedential decision in the PCSK9 litigation between Sanofi and Amgen, the ILPTO granted the opposition against Amgen’s broad claims to PCSK9 antibodies and limited the scope of functional antibody claims. PCSK9 is a key player in plasma cholesterol metabolism. Its inhibition increases the number of the LDL Receptors on cell surface and thus […]

April 4, 2024

ILPTO update: Differences in glycosylation profiles may be sufficient to support PTE eligibility of proteins

In a recent ILPTO PTE update, we reported that the ILPTO rejected a PTE petition for the drug Nexviazyme (avalglucosidase alpha) on the grounds that its registration is not the first regulatory approval permitting the use of the API in view of the previously registered drug Myozime (alglucosidase alfa). These APIs contain the same amino […]

February 8, 2024

When is a novel protein “new” for PTE purposes?

A recent decision of the ILPTO illustrates its restrictive approach with respect to eligibility of modified versions of previously approved proteins for PTE but the final word has not yet been said. The ILPTO rejected a petition to extend the term of a patent claiming the recombinant antihemophilic factor VIII tuoctocog alfa pegol (Esperoct®). The […]

January 28, 2024

ILPTO update: Salt Patents may still be obtained – despite another restrictive ILPTO decision

In a recent decision relating to the tosylate salt of lumateperone, the ILPTO again expressed a highly restrictive view in connection with salt patents. However, salt patents may still be obtained if proper evidence is submitted to establish that the patent is not merely a reflection of routine salt screening. The ILPTO rejected the Patent […]

January 3, 2024

IL Patent Update: Sanctions for misleading representations can target Patentee’s profits

The Supreme Court of Israel held by a majority opinion of an expanded panel that a patentee who willfully provided misleading information to the ILPTO or concealed pertinent information may be liable for restitution of profits derived from delayed generic entry. The judgment results from complex litigation which started more than fifteen years ago and […]

November 7, 2023

The 2023 Legal 500 Israel Patent Litigation Comparative Guide by Liad Whatstein & Co.

Our firm recently published on the Legal 500 platform an updated Israel chapter for 2023 in the Legal 500 Patent Litigation Comparative Guide. The guide can be consulted on Legal 500’s website, or directly on our website.

Protein

June 22, 2023

ILPTO update: PTE Eligibility of Proteins

In a recent decision, the ILPTO Deputy Chief Examiner held that different glycosylation is insufficient to confer PTE eligibility if a protein with the same amino acid sequence was previously approved. The decision is inconsistent with previous ILPTO case law and we expect further clarification of the ILPTO position in the coming months. The ILPTO […]

12
Skip to content